PHP23 PHARMACEUTICAL PRESCRIPTION: COSTS AND FACTORS OF INFLUENCE  by Akremi, J
373Abstracts
Strategies to control the quality and cost of medication use are
largely dependent on the ability to alter selection of medications.
Previous models of prescribing behavior have focused on physi-
cians. In the hospital setting, clinical pharmacists and formulary
committee members are also key players in medication decision-
making. Differences between physicians, formulary committee
members, and clinical pharmacists have not been compared.
Knowledge of these differences could have importance in pre-
dicting the effectiveness of strategies designed to inﬂuence med-
ication use in this setting. OBJECTIVE: The objective of this
study was to describe and compare the opinions of physicians,
clinical pharmacists, and formulary committee members with
respect to key factors that inﬂuence medication prescribing in
community hospitals. METHODS: Physicians, clinical pharma-
cists, and formulary committee members were solicited to 
participate. A trained interviewer administered a standardized
questionnaire designed to elicit opinions of participants regard-
ing the importance of factors thought to inﬂuence the prescrib-
ing of medications. Responses were described using descriptive
statistics, and differences between the groups were determined
by Post hoc analysis. RESULTS: A total of 150 individuals par-
ticipated in the study. Safety, effectiveness, formulary status, and
restrictions on prescribing were considered highly inﬂuential by
all participants. Physicians rated the availability of drug samples,
and personal experience higher (more inﬂuential on prescribing)
than clinical pharmacists and formulary committee members.
Clinical pharmacists and formulary committee members rated
the inﬂuence of recommendations by clinical pharmacists, 
prescribing guidelines, and cost or cost comparisons higher than
physicians. Factors that were drug-related, or that involved
policy-related programs tended to be more inﬂuential than indi-
rect factors. CONCLUSIONS: Those who seek to implement
programs to alter medication use should recognize and employ
factors that are most inﬂuential in the decision-making process.
Further, it may be important to consider differences that exist
between key participants in the medication use process.
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E-COMMERCE ON PHARMACEUTICALS: A POSITIVE TREND
OR A TECHNOLOGICAL DEAMON?
Hatzikou M, Liappis T
Boehringer Ingelheim, Elliniko, Athens, Greece
OBJECTIVE: The concept of e-commerce on pharmaceuticals is
a controversial issue affecting both U.S.A and Europe. This
report will evaluate the beneﬁts and disadvantages of online
pharmacies for consumers, pharmacists, and the pharmaceutical
industry. METHODS: The legal background to online phar-
macies in Europe will be examined in accordance with the 
differential pricing and reimbursement issues of some selected
European countries. The reasons for this phenomenon are going
to be analyzed. The easy access, time saving and privacy are the
main explanations, but what about prices? Is internet an indirect
way of parallel trade in pharmaceuticals? What precautions
should be taken for both patients and companies of e-commerce
in pharmaceuticals? RESULTS: Issues of potential risks to public
health because of handling outside regulated distribution chan-
nels. Additionally, lack of prescription in accordance with arrival
without instructions for proper use or in an incorrect dose might
put the health of the patients in danger. CONCLUSION: The
phenomenon of e-commerce on pharmaceuticals is a “headache”
issue for all the involved parties in the medical world, the doctors
who can’t control their patients medicines, pharmacists who lose
market share, patients who take medicines which in many cases
might cause them side effects because they don’t have the per-
mission of the doctor and last but not least pharmaceutical com-
panies which they can’t control their stocks since patients from
different countries order medicines via internet with lower prices
than they are being sold in their country.
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TRENDS IN APPROVALS BY THE PHARMACEUTICAL
BENEFITS ADVISORY COMMITTEE
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OBJECTIVES: In Australia, drugs are only publicly subsidised
and listed on the Pharmaceutical Beneﬁts Scheme (PBS) if the
Pharmaceutical Beneﬁts Advisory Committee (PBAC) has deter-
mined that the drug is cost effective. This process is in addition
to the regulatory process including the Australian Drug Evalua-
tion Committee (ADEC). Critics of the current scheme have 
commented that requirements of the PBAC have become more
onerous in recent years and that the listing of important new
drugs is being delayed. We sought to analyse all published rec-
ommendations of the PBAC meetings from December 1999 to
June 2003 to determine if there is a relationship between the date
of a drug’s regulatory approval, its PBAC recommendation and
subsequent listing on the PBS. METHODS: There were 4 dates
associated with each application: ADEC meeting date, PBAC
meeting date, projected PBS listing date (the ﬁrst date an
approved drug could be PBS listed) and actual PBS listing date.
We used a logistic regression model to identify variables associ-
ated with successful PBS listing, including the year of the PBAC
meeting, submission type, form of economic analysis and
requested listing restrictions. A second analysis was performed
with the outcome variable being ‘approval within 5 months of
meeting date’, to overcome any bias against 2003 applications
that had a shorter follow-up period. RESULTS: The analysis
showed ‘Year of PBAC meeting’ was statistically signiﬁcant for
successful PBS listing. The other variables were not statistically
signiﬁcant. Using 1999 as the reference year, the odds ratios were
as follows: 2000 = 0.6889, 2001 = 0.5500, 2002 = 0.3917, 2003
= 0.1000. Using the modiﬁed dependent variable (approval
within 5 months) similar results to the above analysis were pro-
duced—the OR for variable Year remained statistically signiﬁ-
cant. CONCLUSIONS: The analysis of factors associated with
PBS listing showed that there was a signiﬁcant downward trend
over the years in successful applications. This trend did not
appear to be associated with the other factors listed.
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OBJECTIVE: In France, for about 30 years, the level of the con-
sumption of pharmacy strongly increased, which increased the
public health insurance expenditure. Policies, who were applied,
increased the costs of the patients. The physicians were blamed
in those drifts. By knowing that the doctor does not have direct
ﬁnancial proﬁts in the recommendation of the pharmacies, we
try to understand if his implication direct or indirect in the
increase of the level of consumption of medication is founded.
This study examines the factors, which inﬂuence the prescription
of medication of the physicians. METHODS: For the empirical
study we used the national base of the data of the French physi-
cians who were observed during the period from 1981 to 2000.
The variables used are the seniority of the physician, the struc-
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ture and the volume of his professional activity, the effects of the
competition and locals’ standards. RESULTS: The behaviour of
the prescription of the physician depend of his type of conven-
tion with the State. At the average, the physicians, who do not
have the convention, prescribe 41 Euro of drugs per act, the
physicians, who have the price of consultation ﬁxed by the State,
prescribe 36 Euro per act and the physicians, who can ﬁx freely
their price, prescribe 30€ per act. The prescription is a regulator
of the level of activity (-3.65 for the physicians without the con-
vention, 0.02 for the rest). We ﬁnd an effect of complement
between the pharmaceutical prescription and the prescription of
sick leaves’ days. Competition has the inﬂuence upon the level
of the regulation. CONCLUSIONS: The result of this study
makes possible to deﬁne the inciting policies on the pharmaceu-
tical regulation to ensure a greater effectiveness of the regulation
of an ambulatory medicine.
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QUALITY OF DECISION-MAKING BY THE PHARMACEUTICAL
BENEFITS ADVISORY COMMITTEE (PBAC) AND THE IMPACT
ON OUTCOMES
Neville AM, Lloyd JM
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OBJECTIVES: In Australia, a drug is subsidised by the govern-
ment only if the Pharmaceutical Beneﬁts Advisory Committee
(PBAC) evaluation has determined the drug to be cost effective.
The government reviewed the quality of industry pharmacoeco-
nomic analyses included in PBAC submission documents and
reported that signiﬁcant problems existed. It is likely, however,
that the PBAC evaluation process itself could contain errors. We
sought to determine the quality of the PBAC evaluations, their
effect on decision-making and the outcomes of PBAC meetings.
METHODS: A survey was conducted to determine industry
experience regarding PBAC decision-making over a period of six
PBAC meetings. The questionnaire was designed to elicit infor-
mation on good and poor decisions, and information needed to
quantify the issues and their effects on submission outcomes. The
questionnaire was divided into 2 sections, the ﬁrst to elicit infor-
mation on good and poor decisions and the second to quantify
the issues and their effects on submission outcomes. RESULTS:
Of 35 questionnaires sent to pharmaceutical companies in 
Australia, 17 replies were received, a response rate of 48%.
These 17 companies had sales that represented 47% of total
pharmaceutical sales. The survey concluded that on average
good decisions were made by the PBAC for only 56% of all sub-
missions. The quality of the PBAC evaluation was related to the
form of economic argument presented and whether the submis-
sion was a ﬁrst or a subsequent (repeat) submission. If the sub-
mission used a cost-minimisation approach, the likelihood of the
evaluation being good was 69%, compared with 38% for sub-
missions that took a cost-effectiveness approach. The likelihood
of a submission’s success was also related to the form of eco-
nomic analysis used, 92% if cost-minimisation was used versus
63% for a cost-effectiveness approach. CONCLUSIONS: Gov-
ernment subsidy decision-making is of variable quality, which
varies the method of economic argument used and affects the
probability of success for submissions.
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ASSESSMENT OF THE IMPACT OF “ACADEMIC DETAILING”
IN PROMOTING COST-EFFECTIVE GENERIC DRUG
PRESCRIPTION AMONG AMBULATORY CARE PHYSICIANS 
IN WEST VIRGINIA
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OBJECTIVE: Literature suggests that ‘Academic Detailing’ is a
useful ‘evidence-based’ intervention in promoting rational drug
therapy by encouraging appropriate use of cost-effective generic
pharmaceuticals. This study examines possible impact of acade-
mic detailing on trends in change of proportions of generic drug
prescriptions among ambulatory care physicians serving patients
covered by a state health insurance program. METHODS: The
study was conducted using retrospective data available from the
pharmacy beneﬁt management company serving the insurance
program. The target physician population comprised of two
experimental groups (Charleston, n = 251; Morgantown, n =
214)—the top 30th percentile of all the physicians in the areas
chosen based on prescribing volume and average prescription
cost. University-trained academic detailers visited them once
every month and also provided them with educational materials.
A “comparison” group (n = 359) was chosen similarly but was
not visited by a detailer at any time. Monthly generic prescrib-
ing percent were determined for all three groups for a period of
12 months before the intervention and 6 months after the inter-
vention. Two therapeutic classes with ample generic choices—
antibiotics and anti-hypertensives, were studied. RESULTS: In
case of antibiotic prescriptions, while mean increase in percent
generic prescriptions went up in both the experimental groups
(0.26 to 2.41 in Charleston; -0.18 to 2.35 in Morgantown),
mean change in percentage generic prescriptions reduced further
(-0.6 to -3.36) in the comparison group. Though over a much
shorter intervention period—similar trends were observed with
anti-hypertensive prescriptions. In Charleston, there was a sus-
tained (mean rate of change over intervention period = 1.37)
trend in increase in proportion of generic prescriptions while the
proportion declined in the comparison group (mean rate of
change over intervention period = -0.44). CONCLUSIONS:
Academic detailing appears to be a promising strategy for main-
taining or increasing generic prescribing by physicians in ambu-
latory settings.
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1CCOHTA, Ottawa, ON, Canada
OBJECTIVES: The Guidelines is a guidance document to assist
those doing economic evaluations produce standardized and 
reliable economic information for the users of the information
(e.g. decision-makers in Canada’s publicly-funded health care
system). The main changes in this 3rd edition will be discussed.
METHODS: CCOHTA has revised the 1997 edition of the
Guidelines to ensure it remains current, taking into account of
methodological developments and other signiﬁcant changes since
1997. Each Guideline section provides guidance on preferred
methods and advice in areas of controversy. Key stakeholders,
including jurisdictions, industry and methodological experts,
were consulted. Judgement was needed to strike the proper
balance between theoretically ideal vs pragmatic approaches.
RESULTS: Key changes include emphasis on: 1) using cost-
effectiveness and cost-utility analyses; 2) presenting the payer
perspective; 3) using “usual” and recommended care for the
comparator; 4) appropriate analysis of effectiveness parameters;
4) using probabilistic and Bayesian analyses for analyzing uncer-
tainty; 6) using stratiﬁed analysis; and 7) identifying distribu-
tional effects of the technology. Appendices include: 1) guidance
on evaluating non-drug technologies; 2) changes to the stan-
dardized reporting format; 3) guidance on modelling; 4) guid-
ance on reviewing economic studies; 5) quality assurance tips for
doers; and 6) tips for decision-makers on the use and interpre-
